iSonea raises $13.5m to fund AirSonea launch
iSonea (ASX:ISN) has completed a $13.5 million placement to help raise funds for the market launch of its AirSonea mobile wheeze-monitoring device.
The company placed 38.6 million shares with clients of Patersons Securities at $0.35 per share. The allocation represents around 17.5% of the company’s share capital.
iSonea CEO Michael Thomas said the additional cash will be used to fund the Australian launch of AirSonea later this year and its debut in the US in early 2014.
“This key fundraising enables [us] to focus on ensuring the AirSonea product commercialisation is properly funded across every aspect of the launch, from product manufacturing and distribution channel management, right through to ... marketing and sales,” he said.
The company last month selected a manufacturing partner for the device. Hong Kong-based Refined Manufacturing, which produced several prototype AirSonea units, has secured the contract.
iSonea has also been conducting market research in the lead-up to the Australian launch.
iSonea shares were trading 2.04% lower at $0.48 as of around 12.30 pm on Tuesday.
Even non-antibiotics can disrupt the microbiome
Many non-antibiotics inhibit useful gut bacteria, giving rise to an imbalance in the microbiome,...
How brain stem cells move between resting and active states
Understanding this process is crucial, because it underpins how the brain repairs itself and...
Accurate age estimation with DNA methylation
Using cutting-edge artificial intelligence, scientists created a tool that can determine a...
